Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 Shares

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) CFO Dominic Piscitelli sold 1,034 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $10.00, for a total transaction of $10,340.00. Following the transaction, the chief financial officer now owns 100,783 shares of the company's stock, valued at $1,007,830. This trade represents a 1.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Dominic Piscitelli also recently made the following trade(s):

• On Tuesday, June 24th, Dominic Piscitelli sold 32,466 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.50, for a total transaction of $340,893.00.
• On Thursday, June 12th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Wednesday, June 11th, Dominic Piscitelli sold 2,976 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total transaction of $29,789.76.
• On Tuesday, June 10th, Dominic Piscitelli sold 324 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,240.00.
• On Monday, June 9th, Dominic Piscitelli sold 300 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.00, for a total transaction of $3,000.00.
• On Friday, June 6th, Dominic Piscitelli sold 2,600 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $10.01, for a total transaction of $26,026.00.

Oric Pharmaceuticals Trading Up 4.9%

ORIC traded up $0.49 on Tuesday, hitting $10.49. 1,161,709 shares of the company were exchanged, compared to its average volume of 787,784. The business's fifty day moving average is $6.82 and its 200 day moving average is $7.68. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09. On average, research analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Oric Pharmaceuticals from $21.00 to $22.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Guggenheim reiterated a "buy" rating on shares of Oric Pharmaceuticals in a research report on Wednesday, February 26th. Oppenheimer decreased their price objective on Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and issued a $21.00 target price on shares of Oric Pharmaceuticals in a research note on Monday, May 5th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $19.17.

Institutional Investors Weigh In On Oric Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS acquired a new stake in Oric Pharmaceuticals in the 4th quarter valued at about $50,000. Arizona State Retirement System acquired a new stake in Oric Pharmaceuticals in the 1st quarter valued at about $56,000. BNP Paribas Financial Markets acquired a new stake in Oric Pharmaceuticals in the 4th quarter valued at about $71,000. Hsbc Holdings PLC acquired a new stake in Oric Pharmaceuticals in the 1st quarter valued at about $102,000. Finally, PNC Financial Services Group Inc. grew its stake in Oric Pharmaceuticals by 22.9% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company's stock valued at $109,000 after acquiring an additional 2,520 shares during the last quarter. 95.05% of the stock is owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.